Research programme: CovX-Bodies - Pfizer

Drug Profile

Research programme: CovX-Bodies - Pfizer

Alternative Names: CVX 37; CVX-22; CVX-63

Latest Information Update: 15 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CovX
  • Class Antibodies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin-2 inhibitors; Glucagon like peptide 1 receptor agonists; HIV fusion inhibitors; Thrombospondin 1 agonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Diabetes mellitus
  • Discontinued HIV infections

Most Recent Events

  • 28 Oct 2009 This programme is still in active development
  • 10 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section
  • 26 Apr 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the Cancer pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top